Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Hematopoietic and Lymphoid Cell Neoplasm
- Hodgkin Lymphoma
- Myelodysplastic Syndrome
- Non Hodgkin Lymphoma
- Plasma Cell Myeloma
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. Evaluate cardiovascular reserve capacity, as measured by peak oxygen consumption (VO2peak), in hematopoietic cell transplantation (HCT) survivors. II. Define the determinants of VO2peak impairment in HCT survivors. OUTLINE: Patients undergo echocardiogram to assess cardiac fun...
PRIMARY OBJECTIVES: I. Evaluate cardiovascular reserve capacity, as measured by peak oxygen consumption (VO2peak), in hematopoietic cell transplantation (HCT) survivors. II. Define the determinants of VO2peak impairment in HCT survivors. OUTLINE: Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.
Tracking Information
- NCT #
- NCT04537871
- Collaborators
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Investigators
- Principal Investigator: Saro H Armenian City of Hope Comprehensive Cancer Center
Get Well Soon